Christopher Mark Jones

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Somnath Mukherjee · 4 shared papers, 2020–2024 · strength 0.47
   • Paper Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally ad… DOI 10.1016/j.ejca.2024.114236↗
   • Paper Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradio… DOI 10.1038/s41416-020-01120-z↗
   • Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
2. D. Holyoake · 3 shared papers, 2020–2024 · strength 0.35
   • Paper Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally ad… DOI 10.1016/j.ejca.2024.114236↗
   • Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
   • Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
3. Ganesh Radhakrishna · 3 shared papers, 2020–2024 · strength 0.35
   • Paper Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally ad… DOI 10.1016/j.ejca.2024.114236↗
   • Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
   • Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
4. M. Hawkins · 3 shared papers, 2020–2024 · strength 0.35
   • Paper Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally ad… DOI 10.1016/j.ejca.2024.114236↗
   • Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
   • Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
5. Pippa G. Corrie · 3 shared papers, 2020–2024 · strength 0.35
   • Paper Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally ad… DOI 10.1016/j.ejca.2024.114236↗
   • Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
   • Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
6. Tim Maughan · 2 shared papers, 2021–2024 · strength 0.27
   • Paper Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally ad… DOI 10.1016/j.ejca.2024.114236↗
   • Paper Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradio… DOI 10.1038/s41416-020-01120-z↗
7. Chris N Hurt · 2 shared papers, 2021–2024 · strength 0.27
   • Paper Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally ad… DOI 10.1016/j.ejca.2024.114236↗
   • Paper Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradio… DOI 10.1038/s41416-020-01120-z↗
8. Eric E. O’Neill · 2 shared papers, 2021–2024 · strength 0.27
   • Paper Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally ad… DOI 10.1016/j.ejca.2024.114236↗
   • Paper Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradio… DOI 10.1038/s41416-020-01120-z↗
9. James S. Good · 2 shared papers, 2020–2021 · strength 0.19
   • Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
   • Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
10. Paula Ghaneh · 2 shared papers, 2020–2021 · strength 0.19
    • Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
    • Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
11. Derek B. Grose · 2 shared papers, 2020–2021 · strength 0.19
    • Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
    • Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
12. Katharine L. Aitken · 2 shared papers, 2020–2021 · strength 0.19
    • Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
    • Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
13. Daniel H. Palmer · 2 shared papers, 2020–2021 · strength 0.19
    • Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
    • Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
14. Nigel Balfour Jamieson · 2 shared papers, 2020–2021 · strength 0.19
    • Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
    • Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
15. Juan W. Valle · 2 shared papers, 2020–2021 · strength 0.19
    • Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
    • Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
16. Thankamma Ajithkumar · 1 shared paper, 2024 · strength 0.16
    • Paper Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally ad… DOI 10.1016/j.ejca.2024.114236↗
17. Harpreet Singh Wasan · 1 shared paper, 2024 · strength 0.16
    • Paper Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally ad… DOI 10.1016/j.ejca.2024.114236↗
18. Frances W. Willenbrock · 1 shared paper, 2021 · strength 0.12
    • Paper Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradio… DOI 10.1038/s41416-020-01120-z↗
19. Daniel Llwyd Hughes · 1 shared paper, 2021 · strength 0.12
    • Paper Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradio… DOI 10.1038/s41416-020-01120-z↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.